Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

§
Marginalia
Code · STATUTE-COMPILATIONS · Food and Drug Administration Safety and Innovation Act · Sec. 2

Sec. 2. TABLE OF CONTENTS; REFERENCES IN ACT

1,086 words·~5 min read·/statute-compilations/comps-9932/sec-2

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

## SEC. 2 TABLE OF CONTENTS; REFERENCES IN ACT ###
(a)Table of Contents The table of contents of this Act is as follows: Sec. 1. Short title. Sec. 2. Table of contents; references in Act. TITLE I—FEES RELATING TO DRUGS Sec. 101. Short title; finding. Sec. 102. Definitions. Sec. 103. Authority to assess and use drug fees. Sec. 104. Reauthorization; reporting requirements. Sec. 105. Sunset dates. Sec. 106. Effective date. Sec. 107. Savings clause. TITLE II—FEES RELATING TO DEVICES Sec. 201. Short title; findings. Sec. 202. Definitions. Sec. 203. Authority to assess and use device fees. Sec. 204. Reauthorization; reporting requirements. Sec. 205. Savings clause. Sec. 206. Effective date. Sec. 207. Sunset clause. Sec. 208. Streamlined hiring authority to support activities related to the process for the review of device applications. TITLE III—FEES RELATING TO GENERIC DRUGS Sec. 301. Short title. Sec. 302. Authority to assess and use human generic drug fees. Sec. 303. Reauthorization; reporting requirements. Sec. 305. Effective date. Sec. 306. Amendment with respect to misbranding. Sec. 307. Streamlined hiring authority to support activities related to human generic drugs. Sec. 308. Additional reporting requirements. TITLE IV—FEES RELATING TO BIOSIMILAR BIOLOGICAL PRODUCTS Sec. 401. Short title; finding. Sec. 402. Fees relating to biosimilar biological products. Sec. 403. Reauthorization; reporting requirements. Sec. 405. Effective date. Sec. 406. Savings clause. Sec. 407. Conforming amendment. Sec. 408. Additional reporting requirements. TITLE V—PEDIATRIC DRUGS AND DEVICES Sec. 501. Permanence. Sec. 502. Written requests. Sec. 503. Communication with Pediatric Review Committee. Sec. 504. Access to data. Sec. 505. Ensuring the completion of pediatric studies. Sec. 506. Pediatric study plans. Sec. 507. Reauthorizations. Sec. 508. Report. Sec. 509. Technical amendments. Sec. 510. Pediatric rare diseases. Sec. 511. Staff of Office of Pediatric Therapeutics. TITLE VI—MEDICAL DEVICE REGULATORY IMPROVEMENTS Sec. 601. Investigational device exemptions. Sec. 602. Clarification of least burdensome standard. Sec. 603. Agency documentation and review of significant decisions. Sec. 604. Device modifications requiring premarket notification prior to marketing. Sec. 605. Program to improve the device recall system. Sec. 606. Clinical holds on investigational device exemptions. Sec. 607. Modification of de novo application process. Sec. 608. Reclassification procedures. Sec. 609. Harmonization of device premarket review, inspection, and labeling symbols. Sec. 610. Participation in international fora. Sec. 611. Reauthorization of third-party review. Sec. 612. Reauthorization of third-party inspection. Sec. 613. Humanitarian device exemptions. Sec. 614. Unique device identifier. Sec. 615. Sentinel. Sec. 616. Postmarket surveillance. Sec. 617. Custom devices. Sec. 618. Health information technology. Sec. 619. Good guidance practices relating to devices. Sec. 620. Pediatric device consortia. TITLE VII—DRUG SUPPLY CHAIN Sec. 701. Registration of domestic drug establishments. Sec. 702. Registration of foreign establishments. Sec. 703. Identification of drug excipient information with product listing. Sec. 704. Electronic system for registration and listing. Sec. 705. Risk-based inspection frequency. Sec. 706. Records for inspection. Sec. 707. Prohibition against delaying, denying, limiting, or refusing inspection. Sec. 708. Destruction of adulterated, misbranded, or counterfeit drugs offered for import. Sec. 709. Administrative detention. Sec. 710. Exchange of information. Sec. 711. Enhancing the safety and quality of the drug supply. Sec. 712. Recognition of foreign government inspections. Sec. 713. Standards for admission of imported drugs. Sec. 714. Registration of commercial importers. Sec. 715. Notification. Sec. 716. Protection against intentional adulteration. Sec. 717. Penalties for counterfeiting drugs. Sec. 718. Extraterritorial jurisdiction. TITLE VIII—GENERATING ANTIBIOTIC INCENTIVES NOW Sec. 801. Extension of exclusivity period for drugs. Sec. 802. Priority review. Sec. 803. Fast track product. Sec. 804. Clinical trials. Sec. 805. Reassessment of qualified infectious disease product incentives in 5 years. Sec. 806. Guidance on pathogen-focused antibacterial drug development. TITLE IX—DRUG APPROVAL AND PATIENT ACCESS Sec. 901. Enhancement of accelerated patient access to new medical treatments. Sec. 902. Breakthrough therapies. Sec. 903. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. Sec. 904. Accessibility of information on prescription drug container labels by visually impaired and blind consumers. Sec. 905. Risk-benefit framework. Sec. 906. Grants and Contracts for the Development of Orphan Drugs. Sec. 907. Reporting of inclusion of demographic subgroups in clinical trials and data analysis in applications for drugs, biologics, and devices. Sec. 908. Rare pediatric disease priority review voucher incentive program. TITLE X—DRUG SHORTAGES Sec. 1001. Discontinuance or interruption in the production of life-saving drugs. Sec. 1002. Annual reporting on drug shortages. Sec. 1003. Coordination; task force and strategic plan. Sec. 1004. Drug shortage list. Sec. 1005. Quotas applicable to drugs in shortage. Sec. 1006. Attorney General report on drug shortages. Sec. 1007. Hospital repackaging of drugs in shortage. Sec. 1008. Study on drug shortages. TITLE XI—OTHER PROVISIONS Subtitle A—Reauthorizations Sec. 1101. Reauthorization of provision relating to exclusivity of certain drugs containing single enantiomers. Sec. 1102. Reauthorization of the critical path public-private partnerships. Subtitle B—Medical Gas Product Regulation Sec. 1111. Regulation of medical gases. Sec. 1112. Changes to regulations. Sec. 1113. Rules of construction. Subtitle C—Miscellaneous Provisions Sec. 1121. Guidance document regarding product promotion using the Internet. Sec. 1122. Combating prescription drug abuse. Sec. 1123. Optimizing global clinical trials. Sec. 1124. Advancing regulatory science to promote public health innovation. Sec. 1125. Information technology. Sec. 1126. Nanotechnology. Sec. 1127. Online pharmacy report to Congress. Sec. 1128. Report on small businesses. Sec. 1129. Protections for the commissioned corps of the public health service act. Sec. 1130. Compliance date for rule relating to sunscreen drug products for over-the-counter human use. Sec. 1131. Strategic integrated management plan. Sec. 1132. Assessment and modification of REMS. Sec. 1133. Extension of period for first applicant to obtain tentative approval without forfeiting 180-day-exclusivity period. Sec. 1134. Deadline for determination on certain petitions. Sec. 1135. Final agency action relating to petitions and civil actions. Sec. 1136. Electronic submission of applications. Sec. 1137. Patient participation in medical product discussions. Sec. 1138. Ensuring adequate information regarding pharmaceuticals for all populations, particularly underrepresented subpopulations, including racial subgroups. Sec. 1139. Scheduling of hydrocodone. Sec. 1140. Study on Drug Labeling by Electronic Means. Sec. 1141. Recommendations on interoperability standards. Sec. 1142. Conflicts of interest. Sec. 1143. Notification of FDA intent to regulate laboratory-developed tests. Subtitle D—Synthetic Drugs Sec. 1151. Short title. Sec. 1152. Addition of synthetic drugs to schedule I of the Controlled Substances Act. Sec. 1153. Temporary scheduling to avoid imminent hazards to public safety expansion. ###
(b)References in Act Except as otherwise specified, amendments made by this Act to a section or other provision of law are amendments to such section or other provision of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.). # TITLE I FEES RELATING TO DRUGS
Connectionstraces to 1
Traces to 1 document
Citation graph
cites case law
Sec. 2
TABLE OF CONTENTS; REFERENCES IN ACT
U.S.C.§ 301
Cites 1Cited by 0 across 0 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.